---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-056966"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T05:11:57.366151+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nektar Therapeutics raises $30M via pre-funded warrant to TCG Crossover Fund

## Summary
- Issued pre-funded warrant to purchase 25M shares of common stock at $1.20 per share, total $30M.
- Exercise price of warrant is $0.0001 per share; purchaser cannot exceed 9.99% beneficial ownership without notice.
- Closing expected on or before March 6, 2024; exempt from registration under Section 4(a)(2) and Rule 506(b).
- Company to file resale registration statement for warrant shares within 90 days after closing.
- Use of proceeds not specified; proceeds before expenses are $30M.

## SEC filing metadata
- accession: 0001193125-24-056966
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000119312524056966/0001193125-24-056966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000119312524056966/d762406d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-056966
- JSON: https://secwatch.observer/filing/0001193125-24-056966.json
- Plain text: https://secwatch.observer/filing/0001193125-24-056966.txt

## Key facts
- Material Agreements
  NEKTAR THERAPEUTICS entered into Purchase Agreement with TCG Crossover Fund II, L.P. valued at $30.0 million (effective 2024-03-04).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: TCG Crossover Fund II, L.P.
  - Value: $30.0 million
  - Effective: 2024-03-04
  source text: On March 4, 2024, Nektar Therapeutics (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with TCG Crossover Fund II, L.P. (the “Purchaser”), for the private placement (the “Private Placement”) of a pre-funded warrant (the “Pre-Funded Warrant”) to purchase 25,000,000 shares of the Company’s common stock (the “Common Stock”), par value $0.0001 per share (the “Warrant Shares” and together with the Pre-Funded Warrant, the “Securities”), at a total purchase price of $30.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000119312524056966/0001193125-24-056966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.